- Home
- JQC vs PLRX Comparison
JQC vs PLRX Comparison
Compare JQC & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JQC
- PLRX
- Stock Information
- Founded
- JQC 2003
- PLRX 2015
- Country
- JQC United States
- PLRX United States
- Employees
- JQC N/A
- PLRX N/A
- Industry
- JQC Finance Companies
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- JQC Finance
- PLRX Health Care
- Exchange
- JQC Nasdaq
- PLRX Nasdaq
- Market Cap
- JQC 771.6M
- PLRX 682.2M
- IPO Year
- JQC N/A
- PLRX 2020
- Fundamental
- Price
- JQC $5.56
- PLRX $11.07
- Analyst Decision
- JQC
- PLRX Strong Buy
- Analyst Count
- JQC 0
- PLRX 7
- Target Price
- JQC N/A
- PLRX $40.50
- AVG Volume (30 Days)
- JQC 714.6K
- PLRX 544.0K
- Earning Date
- JQC 01-01-0001
- PLRX 02-26-2025
- Dividend Yield
- JQC 11.13%
- PLRX N/A
- EPS Growth
- JQC N/A
- PLRX N/A
- EPS
- JQC N/A
- PLRX N/A
- Revenue
- JQC N/A
- PLRX N/A
- Revenue This Year
- JQC N/A
- PLRX N/A
- Revenue Next Year
- JQC N/A
- PLRX N/A
- P/E Ratio
- JQC N/A
- PLRX N/A
- Revenue Growth
- JQC N/A
- PLRX N/A
- 52 Week Low
- JQC $4.82
- PLRX $10.22
- 52 Week High
- JQC $5.65
- PLRX $18.92
- Technical
- Relative Strength Index (RSI)
- JQC 35.08
- PLRX 36.41
- Support Level
- JQC $5.59
- PLRX $10.94
- Resistance Level
- JQC $5.68
- PLRX $12.70
- Average True Range (ATR)
- JQC 0.08
- PLRX 0.77
- MACD
- JQC -0.01
- PLRX -0.18
- Stochastic Oscillator
- JQC 16.13
- PLRX 4.69
About JQC Nuveen Credit Strategies Income Fund Shares of Beneficial Interest
Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.